NCT05373745 is a NA clinical trial of Active Brains 1 in Chronic Pain, sponsored by Massachusetts General Hospital.

Who is sponsoring NCT05373745?

NCT05373745 is sponsored by Massachusetts General Hospital.

What drugs are being tested in NCT05373745?

Interventions in NCT05373745: Active Brains 1, Active Brains 2.

What condition does NCT05373745 study?

NCT05373745 studies Chronic Pain, Mild Cognitive Impairment, Older Adults, Physical Activity.

Is NCT05373745 still recruiting?

NCT05373745 is currently active, enrolled. Last updated 23 February 2026.

Last reviewed 2026-02-23 · How we verify

NCT05373745

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Managing Pain and Cognitions in Older Adults With Early Cognitive Decline and Chronic Pain

Active, enrolled NA Last updated 23 February 2026

What this trial tests

NA trial testing Active Brains 1 in Chronic Pain in 260 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

20 June 2022

Primary endpoint
31 December 2025

31 December 2026

Quick facts

Lead sponsor	Massachusetts General Hospital
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	260
Start date	20 June 2022
Primary completion	31 December 2025
Estimated completion	31 December 2026
Sites	1 location across United States

Drugs / interventions tested

Active Brains 1
Active Brains 2

Conditions studied

Chronic Pain — all drugs for Chronic Pain →
Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
Older Adults — all drugs for Older Adults →
Physical Activity — all drugs for Physical Activity →

Sponsor

Massachusetts General Hospital

Who can join

60 and older, any sex, with Chronic Pain or Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators aim to conduct a fully powered randomized controlled trial to compare the efficacy of two symptom management programs for older adults with early cognitive decline (either self-reported or confirmed by testing) and chronic pain, Active Brains 1 and Active Brains 2. The investigators will assess how each program may help in improving multimodal physical, cognitive and emotional function. The investigators will also assess whether improvements in outcomes from the two programs are maintained through 6-months follow-up. The investigators will also explore whether improvements in outcomes are mediated by nonadaptive pain reactions, adaptive coping, social factors and compensatory strategies and modified by demographic and clinical predictors. Both programs will be delivered virtually (Zoom).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Addressing the Chronic Pain-Early Cognitive Decline Comorbidity Among Older Adults: Protocol for the Active Brains Remote Efficacy Trial.
Vranceanu AM, Choukas NR, Rochon EA, Duarte B, et al · · 2023 · cited 8× · PMID 37768713 · DOI 10.2196/47319

Verify or expand the search:

Other trials of Active Brains 1

Trials testing the same drug.

NCT04044183 — Managing Pain and Cognitions in Older Adults With Mild Cognitive Impairment or Memory Related Problems and Chronic Pain · NA · completed

Other recruiting trials for Chronic Pain

Currently open trials in the same condition.

NCT07491549 — The Effect of Pain Education Group Therapy and Its Impact on Chronic Pain, Kinesiophobia, and Physical Activity · NA · recruiting
NCT07425691 — SPACE for Youth With Chronic Pain · recruiting
NCT07103135 — Optimizing Accelerated TMS for Chronic Pain With Thompson Sampling · Phase 1 · recruiting
NCT06219408 — CIH Stepped Care for Co-occurring Chronic Pain and PTSD · NA · recruiting
NCT07270406 — Healthy Behaviors for Insomnia Prevention in People With HIV and Ongoing Pain · NA · recruiting

Other Massachusetts General Hospital trials

Trials by the same sponsor.

NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05373745 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 23 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05373745.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing